Drug Screening Market by Offering (On-site Testing, Rapid Testing (Urine, Oral), Analytical (Breathalyzer, Immunoassay, Chromatography)), Sample (Blood, Urine, Hair), Drug (Cannabis, Alcohol), End User (Workplace, Law, Hospitals) - Global Forecast to 2030

The global drug screening market is projected to reach USD 21.29 billion by 2030 from USD 10.36 billion in 2025, at a CAGR of 15.5%. The drug screening market is being driven by expanding government mandates and risk-based testing across safety-sensitive sectors such as transportation, construction, and manufacturing. This growth is underpinned by rising global substance use. Around 316 million people worldwide used drugs in 2023, a rate increasing faster than population growth, heightening impairment risks in workplaces and on public roads. Drug-related impairment is a critical contributor to road traffic injuries (RTIs), which cause approximately 1.3 million deaths annually, with 93% occurring in low- and middle-income countries, reinforcing the need for roadside and post-incident drug testing programs globally. In the US, post-accident workplace drug positivity reached 10.4% in 2023, with marijuana positivity rising to a 25-year high of 7.5%, illustrating similar risk patterns in mature markets and accelerating adoption of random and post-incident testing. As a result, employers and regulators are prioritizing fast, legally defensible screening and confirmatory solutions, while hospitals increasingly rely on high-throughput LC-MS definitive toxicology testing to support critical clinical decisions. At the same time, broader acceptance of oral fluid, saliva, and hair testing is reshaping testing protocols by enabling more accurate detection of recent drug use with lower tampering risk, compelling organizations to upgrade conventional drug screening technologies in response to rising impairment rates and stricter accreditation standards.

“By offering, services segment to account for largest market share”

Based on offering, the services segment, which includes laboratory testing services and onsite testing services, is anticipated to fuel the drug screening market over the forecast period, as organizations continue to adopt comprehensive and managed testing services. Laboratory testing services assist in dealing with a large number of tests, confirmatory tests, and regulatory requirements, whereas onsite testing services facilitate rapid testing at the point of need. The rising trend of compliance-driven, random, and multi-panel testing programs, as well as the increasing use of alternative specimen types such as oral fluid and hair, is driving the demand for specialized service providers. This is also evident in the operational trends, which highlight that, according to the 2023 Quest Diagnostics Drug Testing Index, incidents of workforce test cheating jumped sharply, indicating the growing complexity and need for expert management and confirmatory services. In addition, workplace trends in 2025 highlight that scalability, regulatory compliance, and integrated reporting are key drivers for organizations outsourcing drug testing, rather than managing testing programs in-house. As testing volumes and expenses increase, organizations are increasingly adopting scalable, compliant, and service-oriented drug screening solutions, which support robust growth in the services market. In December 2022, Omega Laboratories launched the Urine Drugs of Abuse Testing Services in its state-of-the-art laboratory in Ontario, Canada. The laboratory offered urine drug testing from January 3, 2023, to complement its molecular testing.

“By end user, drug testing laboratories accounted for largest share of drug screening market in 2024.”

The global drug screening market is fueled by the growing prevalence of illicit drug use, occupational health and safety concerns, and changing medical and legal needs. Globally, it is estimated that 9% of the adult population between 15 and 64 years of age uses illicit drugs every year, with cannabis, opioids, and stimulants being the most prevalent, while drug-related deaths contribute to approximately 0.6 million deaths annually, emphasizing a substantial public health problem. In Europe, cannabis use is a problem for 8.4 % of adults, and drug-related deaths continue to increase, largely due to opioids and polysubstance use. These factors are fueling increasing post-incident, random, and routine drug screening in the workplace in safety-sensitive industries worldwide. The increasing use of non-invasive specimen types, such as oral fluid and hair, as well as the expansion of roadside and law enforcement drug testing, is improving the detection of recent drug use and preventing sample tampering.

“APAC to witness the highest growth rate during the forecast period”

The increasing prevalence of substance use and the structural need for outsourced laboratory testing are driving the market in Asia Pacific. In Australia, the 2022-2023 National Drug Strategy Household Survey estimates that 1.8 million people smoke daily, 2.5 million people have used cannabis in the past 12 months, 1.0 million people have used cocaine, and 6.6 million people engage in risky alcohol consumption, reflecting the continued demand for clinical toxicology and substance monitoring services in healthcare and occupational settings. Moreover, illicit substance use, including cocaine and e-cigarettes, is rising among young adults and women, expanding the tested population beyond the traditional high-risk group. In India, the numbers are even more substantial. National survey data show that 14.6% of the population (approximately 160 million people) are current alcohol users, 31 million people use cannabis, and over 20 million people use opioids, with nearly 6 million people in need of treatment services. Furthermore, 11.8 million people misuse sedatives, and an estimated 850,000 people inject drugs, representing a continued need for laboratory-based toxicology testing in hospitals, rehabilitation facilities, and public health settings.

The breakdown of primary participants is as given below:

• By Company Type - Tier 1: 60%, Tier 2: 30%, and Tier 3: 10%
• By Designation - C-level: 30%, Director-level: 50%, and Others: 20%
• By Region - North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the world: 10%.

Labcorp (US), Quest Diagnostics Incorporated (US), and Abbott (US) are some of the key players in the drug screening market.

• The study includes an in-depth competitive analysis of these key players in the drug screening market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the drug screening market by offering (products & services), sample type (urine samples, breath samples, oral fluid samples, hair samples, other samples), drug type (cannabis, alcohol, cocaine, opioids, amphetamine and methamphetamine, other drugs) end user (drug testing laboratories, workplaces, criminal justice systems and law enforcement agencies, hospitals, drug treatment centers, individual users, pain management centers, schools and colleges, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the drug screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the drug screening market. Competitive analysis of upcoming startups in the drug screening market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the drug screening market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing consumption of illicit drugs and alcohol, Enforcement of stringent laws mandating drug and alcohol testing, Increasing number of regulatory approvals for drug screening products and services) restraints (Ban on alcohol consumption in Islamic countries, Prohibition on workplace drug testing) opportunities (Popularity of oral fluid testing, Introduction of fingerprint-based drug testing at workplaces, High growth opportunities in emerging economies) challenges (Accuracy and specificity concerns in breathalyzers, False positive and negative results in drug screening) influencing the growth of the drug screening market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the drug screening market
• Market Development: Comprehensive information about lucrative markets; the report analyses the drug screening market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the drug screening market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like LabCorp (US), Quest Diagnostics Incorporated (US), Abbott (US), OraSure Technologies Inc. (US), Alfa Scientific Designs Inc. (US), Thermo Fisher Scientific Inc. (US), and Drägerwerk AG & Co. KGaA (Germany), among others, in the drug screening market

Show more